S0800 Safety and Efficacy of Vedolizumab vs Tumor Necrosis Factor Antagonists in an Elderly IBD Population

The American Journal of Gastroenterology ◽

10.14309/01.ajg.0000705248.77205.de ◽

2020 ◽

Vol 115 (1) ◽

pp. S410-S410

Author(s):

C. Alex Wiles ◽

Baldeep S. Pabla ◽

Chris Slaughter ◽

Elizabeth Scoville ◽

Robin Dalal ◽

...

Keyword(s):

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Safety And Efficacy ◽

Tumor Necrosis Factor Antagonists ◽

Necrosis Factor

Download Full-text

Safety and Efficacy of the Tumor Necrosis Factor Antagonists

Seminars in Cutaneous Medicine and Surgery ◽

10.1016/j.sder.2010.02.002 ◽

2010 ◽

Vol 29 (1) ◽

pp. 35-47 ◽

Author(s):

F. Bachmann ◽

A. Nast ◽

W. Sterry ◽

S. Philipp

Keyword(s):

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Safety And Efficacy ◽

Tumor Necrosis Factor Antagonists ◽

Necrosis Factor

Download Full-text

Faculty Opinions recommendation of A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1160775.622184 ◽

2009 ◽

Author(s):

Cyrus Tamboli

Keyword(s):

Tumor Necrosis Factor ◽

Drug Administration ◽

Safety Assessment ◽

Tumor Necrosis ◽

Food And Drug Administration ◽

Tumor Necrosis Factor Antagonists ◽

Necrosis Factor

Download Full-text

Faculty Opinions recommendation of Efficacy of vedolizumab induction and maintenance therapy in patients with ulcerative colitis, regardless of prior exposure to tumor necrosis factor antagonists.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726749172.793568149 ◽

2019 ◽

Author(s):

Ashish Patel

Keyword(s):

Ulcerative Colitis ◽

Tumor Necrosis Factor ◽

Maintenance Therapy ◽

Tumor Necrosis ◽

Prior Exposure ◽

Tumor Necrosis Factor Antagonists ◽

Necrosis Factor

Download Full-text

Faculty Opinions recommendation of Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.732092122.793568144 ◽

2019 ◽

Author(s):

Ashish Patel

Keyword(s):

Inflammatory Bowel Disease ◽

Tumor Necrosis Factor ◽

Bowel Disease ◽

Tumor Necrosis ◽

Tumor Necrosis Factor Antagonists ◽

Inflammatory Bowel ◽

Necrosis Factor

Download Full-text

Safety and Efficacy of a Soluble P75 Tumor Necrosis Factor Receptor (Enbrel, Etanercept) in Patients With Advanced Heart Failure

Circulation ◽

10.1161/01.cir.99.25.3224 ◽

1999 ◽

Vol 99 (25) ◽

pp. 3224-3226 ◽

Author(s):

Anita Deswal ◽

Biykem Bozkurt ◽

Yukihiro Seta ◽

Semahat Parilti-Eiswirth ◽

F. Ann Hayes ◽

...

Keyword(s):

Heart Failure ◽

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Tumor Necrosis Factor Receptor ◽

Advanced Heart Failure ◽

Safety And Efficacy ◽

Necrosis Factor

Download Full-text

Safety and Efficacy of Vedolizumab Versus Tumor Necrosis Factor α Antagonists in an Elderly IBD Population: A Single Institution Retrospective Experience

Digestive Diseases and Sciences ◽

10.1007/s10620-021-07129-5 ◽

2021 ◽

Author(s):

Baldeep S. Pabla ◽

C. Alex Wiles ◽

James C. Slaughter ◽

Elizabeth A. Scoville ◽

Robin L. Dalal ◽

...

Keyword(s):

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Tumor Necrosis Factor Α ◽

Single Institution ◽

Safety And Efficacy ◽

Factor Α ◽

Necrosis Factor

Download Full-text

P154 PRIMARY NON-RESPONSE TO TUMOR NECROSIS FACTOR ANTAGONISTS IS ASSOCIATED WITH INFERIOR RESPONSE TO SECOND-LINE BIOLOGICS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES: A SYSTEMATIC REVIEW AND META-ANALYSIS

Gastroenterology ◽

10.1053/j.gastro.2017.11.204 ◽

2018 ◽

Vol 154 (1) ◽

pp. S81-S82

Author(s):

Siddharth Singh ◽

John George ◽

Brigid S. Boland ◽

Niels Vande Casteele ◽

William J. Sandborn

Keyword(s):

Systematic Review ◽

Tumor Necrosis Factor ◽

Inflammatory Bowel Diseases ◽

Tumor Necrosis ◽

Meta Analysis ◽

Second Line ◽

Tumor Necrosis Factor Antagonists ◽

Bowel Diseases ◽

Inflammatory Bowel ◽

Necrosis Factor

Download Full-text

Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists

Clinical Gastroenterology and Hepatology ◽

10.1016/j.cgh.2016.08.044 ◽

2017 ◽

Vol 15 (2) ◽

pp. 229-239.e5 ◽

Author(s):

Brian G. Feagan ◽

David T. Rubin ◽

Silvio Danese ◽

Severine Vermeire ◽

Brihad Abhyankar ◽

...

Keyword(s):

Ulcerative Colitis ◽

Tumor Necrosis Factor ◽

Maintenance Therapy ◽

Tumor Necrosis ◽

Prior Exposure ◽

Tumor Necrosis Factor Antagonists ◽

Necrosis Factor

Download Full-text

Treatment with Tumor Necrosis Factor Antagonists and Their Possible Effects on Morbidity and Mortality in Psoriasis Patients

Psoriasis Forum ◽

10.1177/247553031117a00106 ◽

2011 ◽

Vol 17a (1) ◽

pp. 56-62

Author(s):

Margarita Carlos ◽

Melanie Ortleb

Keyword(s):

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Morbidity And Mortality ◽

Tumor Necrosis Factor Antagonists ◽

Necrosis Factor

Download Full-text

655 Tumor Necrosis Factor Antagonists Are Superior to Ustekinumab and Vedolizumab for the Prevention of Postoperative Recurrence in Adult Crohn's Disease

The American Journal of Gastroenterology ◽

10.14309/01.ajg.0000592156.21664.71 ◽

2019 ◽

Vol 114 (1) ◽

pp. S384-S384

Author(s):

Takahiro Nakamura ◽

Michael Main ◽

Shannon Chang ◽

Benjamin Click ◽

David Hudesman ◽

...

Keyword(s):

Crohn’S Disease ◽

Tumor Necrosis Factor ◽

Crohn's Disease ◽

Tumor Necrosis ◽

Postoperative Recurrence ◽

Tumor Necrosis Factor Antagonists ◽

Necrosis Factor

Download Full-text